In this scenario, LMTKs represent valid and promising therapeutic targets in PCa management, since their overexpression is expected to modify the complex signalling network involving PI3K/Akt/mTOR, RAS/MAPK and AR pathways. The gene discussed is AKT1; the disease is posterior cortical atrophy.